etodolac ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
anti-inflammatory agents, ibufenac derivatives 1103 41340-25-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • etodolac
  • etodine
  • etodolic acid
  • hypen
A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
  • Molecular weight: 287.36
  • Formula: C17H21NO3
  • CLOGP: 3.43
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 2
  • TPSA: 62.32
  • ALOGS: -3.87
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.01 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 69.60 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 90 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
fu (Fraction unbound in plasma) 0.01 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

DateAgencyCompanyOrphan
Jan. 31, 1991 FDA WYETH PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 78.33 14.94 127 6580 310560 63171755
Interstitial lung disease 37.26 14.94 39 6668 61869 63420446
Hepatic function abnormal 19.88 14.94 22 6685 37120 63445195
Cholelithiasis 18.48 14.94 23 6684 43902 63438413
Psoriasis 17.16 14.94 32 6675 86925 63395390
Beta-N-acetyl-D-glucosaminidase increased 16.93 14.94 3 6704 34 63482281

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Gastric haemorrhage 50.50 17.67 23 3336 10238 34943334
Gastrointestinal haemorrhage 43.82 17.67 48 3311 88429 34865143
Gastric ulcer 41.31 17.67 23 3336 15627 34937945
Duodenal ulcer 26.75 17.67 15 3344 10317 34943255
Interstitial lung disease 26.52 17.67 32 3327 65250 34888322
Atypical femur fracture 20.28 17.67 5 3354 329 34953243
Angioedema 19.72 17.67 21 3338 37353 34916219
Erythema multiforme 18.26 17.67 11 3348 8638 34944934
Metamorphopsia 18.00 17.67 5 3354 524 34953048

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 66.77 13.90 114 8068 298802 79437404
Interstitial lung disease 52.20 13.90 61 8121 112539 79623667
Gastric haemorrhage 43.42 13.90 24 8158 15026 79721180
Gastric ulcer 38.16 13.90 30 8152 33875 79702331
Gastrointestinal haemorrhage 33.77 13.90 57 8125 147662 79588544
Duodenal ulcer 21.76 13.90 16 8166 16353 79719853
Osteonecrosis of external auditory canal 17.44 13.90 4 8178 180 79736026
Beta-N-acetyl-D-glucosaminidase increased 15.43 13.90 3 8179 60 79736146
Pneumonia bacterial 15.35 13.90 14 8168 19317 79716889
Off label use 14.80 13.90 46 8136 907169 78829037
Atypical femur fracture 14.21 13.90 8 8174 5181 79731025

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M01AB08 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Acetic acid derivatives and related substances
FDA CS M0001335 Anti-Inflammatory Agents, Non-Steroidal
FDA MoA N0000000160 Cyclooxygenase Inhibitors
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory agent
CHEBI has role CHEBI:35493 anti-pyretic
CHEBI has role CHEBI:50629 COX-2 inhibitor
FDA EPC N0000175722 Nonsteroidal Anti-inflammatory Drug
MeSH PA D000700 Analgesics
MeSH PA D018712 Analgesics, Non-Narcotic
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D018501 Antirheumatic Agents
MeSH PA D052246 Cyclooxygenase 2 Inhibitors
MeSH PA D016861 Cyclooxygenase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Pain indication 22253000
Rheumatoid arthritis indication 69896004 DOID:7148
Osteoarthritis indication 396275006
Juvenile rheumatoid arthritis indication 410795001
Ankylosing spondylitis off-label use 9631008 DOID:7147
Tendinitis off-label use 34840004 DOID:971
Bursitis off-label use 84017003 DOID:2965
Gout off-label use 90560007 DOID:13189
Peptic ulcer contraindication 13200003 DOID:750
Myocardial infarction contraindication 22298006 DOID:5844
Hypertensive disorder contraindication 38341003 DOID:10763
Gastrointestinal ulcer contraindication 40845000
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Blood coagulation disorder contraindication 64779008 DOID:1247
Gastrointestinal hemorrhage contraindication 74474003
Kidney disease contraindication 90708001 DOID:557
Coronary artery bypass graft contraindication 232717009
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Cardiovascular event risk contraindication 395112001
Smokes tobacco daily contraindication 449868002




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Dogs Pain and inflammation associated with osteoarthritis Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
EtoGesic Tablets Boehringer lngelheim Animal Health USA Inc. 1
Etogesic Sterile Injectable Solution Boehringer lngelheim Animal Health USA Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.95 acidic
pKa2 11.17 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Prostaglandin G/H synthase 2 Enzyme INHIBITOR IC50 5.70 CHEMBL CHEMBL
Prostaglandin G/H synthase 1 Enzyme IC50 5.58 DRUG MATRIX

External reference:

IDSource
4019559 VUID
N0000147659 NUI
D00315 KEGG_DRUG
4019559 VANDF
C0059865 UMLSCUI
CHEBI:4909 CHEBI
CHEMBL622 ChEMBL_ID
DB00749 DRUGBANK_ID
D017308 MESH_DESCRIPTOR_UI
3308 PUBCHEM_CID
7185 IUPHAR_LIGAND_ID
3715 INN_ID
2M36281008 UNII
24605 RXNORM
4707 MMSL
8937 MMSL
d00851 MMSL
003587 NDDF
108510003 SNOMEDCT_US
386860005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Etodolac HUMAN PRESCRIPTION DRUG LABEL 1 0093-1118 TABLET, FILM COATED, EXTENDED RELEASE 600 mg ORAL ANDA 30 sections
Etodolac HUMAN PRESCRIPTION DRUG LABEL 1 0093-1118 TABLET, FILM COATED, EXTENDED RELEASE 600 mg ORAL ANDA 30 sections
Etodolac HUMAN PRESCRIPTION DRUG LABEL 1 0093-1122 TABLET, FILM COATED, EXTENDED RELEASE 400 mg ORAL ANDA 30 sections
Etodolac HUMAN PRESCRIPTION DRUG LABEL 1 0093-1122 TABLET, FILM COATED, EXTENDED RELEASE 400 mg ORAL ANDA 30 sections
Etodolac HUMAN PRESCRIPTION DRUG LABEL 1 0093-7172 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL ANDA 30 sections
Etodolac HUMAN PRESCRIPTION DRUG LABEL 1 0093-7172 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL ANDA 30 sections
Etodolac HUMAN PRESCRIPTION DRUG LABEL 1 0185-0675 TABLET, COATED 400 mg ORAL ANDA 26 sections
Etodolac HUMAN PRESCRIPTION DRUG LABEL 1 0185-0675 TABLET, COATED 400 mg ORAL ANDA 26 sections
Etodolac HUMAN PRESCRIPTION DRUG LABEL 1 0185-0687 TABLET, COATED 500 mg ORAL ANDA 26 sections
Etodolac HUMAN PRESCRIPTION DRUG LABEL 1 0185-0687 TABLET, COATED 500 mg ORAL ANDA 26 sections
Etodolac HUMAN PRESCRIPTION DRUG LABEL 1 10544-862 TABLET, FILM COATED 400 mg ORAL ANDA 30 sections
ETODOLAC HUMAN PRESCRIPTION DRUG LABEL 1 16590-092 TABLET 400 mg ORAL ANDA 30 sections
ETODOLAC HUMAN PRESCRIPTION DRUG LABEL 1 16590-488 CAPSULE 300 mg ORAL ANDA 30 sections
Etodolac HUMAN PRESCRIPTION DRUG LABEL 1 16714-497 TABLET, EXTENDED RELEASE 400 mg ORAL ANDA 28 sections
Etodolac HUMAN PRESCRIPTION DRUG LABEL 1 16714-498 TABLET, EXTENDED RELEASE 500 mg ORAL ANDA 28 sections
Etodolac HUMAN PRESCRIPTION DRUG LABEL 1 16714-499 TABLET, EXTENDED RELEASE 600 mg ORAL ANDA 28 sections
Etodolac HUMAN PRESCRIPTION DRUG LABEL 1 21695-049 CAPSULE, GELATIN COATED 300 mg ORAL ANDA 27 sections
Etodolac HUMAN PRESCRIPTION DRUG LABEL 1 21695-050 TABLET, FILM COATED 400 mg ORAL ANDA 30 sections
Etodolac HUMAN PRESCRIPTION DRUG LABEL 1 33261-043 TABLET, FILM COATED 400 mg ORAL ANDA 28 sections
Etodolac HUMAN PRESCRIPTION DRUG LABEL 1 33261-044 TABLET, FILM COATED 500 mg ORAL ANDA 28 sections
Etodolac HUMAN PRESCRIPTION DRUG LABEL 1 35356-711 TABLET, FILM COATED 400 mg ORAL ANDA 30 sections
Etodolac HUMAN PRESCRIPTION DRUG LABEL 1 42254-052 TABLET, FILM COATED 400 mg ORAL ANDA 28 sections
Etodolac HUMAN PRESCRIPTION DRUG LABEL 1 42254-121 CAPSULE 300 mg ORAL ANDA 14 sections
Etodolac HUMAN PRESCRIPTION DRUG LABEL 1 42291-404 CAPSULE 200 mg ORAL ANDA 26 sections
Etodolac HUMAN PRESCRIPTION DRUG LABEL 1 42291-405 CAPSULE 300 mg ORAL ANDA 26 sections
ETODOLAC HUMAN PRESCRIPTION DRUG LABEL 1 42549-511 TABLET, FILM COATED 400 mg ORAL ANDA 30 sections
Etodolac Human Prescription Drug Label 1 42799-111 TABLET, FILM COATED 400 mg ORAL ANDA 25 sections
Etodolac Human Prescription Drug Label 1 42799-112 TABLET, FILM COATED 500 mg ORAL ANDA 25 sections
Etodolac HUMAN PRESCRIPTION DRUG LABEL 1 43063-578 TABLET, FILM COATED 400 mg ORAL ANDA 29 sections
Etodolac HUMAN PRESCRIPTION DRUG LABEL 1 43063-578 TABLET, FILM COATED 400 mg ORAL ANDA 29 sections